Nachrichten zur CRISPR Therapeutics AG Aktie

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $45.06, marking a +1.35% move from the previous day....…

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $44.92, moving -0.51% from the previous trading session....…

CRISPR Therapeutics AG (CRSP) closed at $45.15 in the latest trading session, marking a -1.25% move from the prior day....…

ZUG, Switzerland and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on…

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused…

Dr James Fox takes a closer look at one of the most promising growth stocks, CRISPR Therapeutics. Could this gene-editing…

The stock has been on a wild ride over the past few years....…

Get in on CRISPR Therapeutics before it gets expensive....…

Both stocks are ripe for a rebound....…

Institutional investors might be on to something....…

Kulkarni, Samarth - Vorstand - Tag der Transaktion: 2023-02-27...…

CRISPR Therapeutics AG (CRSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings…

The company said it expects to complete a filing for FDA approval for the treatment by March, highlighting its lead…

Im letzten Geschäftsjahr schrieb das Biotechunternehmen ein Minus von 650 Millionen Dollar. Das schwache Ergebnis hatte sich abgezeichnet....…

Biotechnologie - Das an der Nasdaq kotierte Biotechunternehmen Crispr Therapeutics mit Sitz in Zug hat das Geschäftsjahr 2022 in den roten…

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 39.22% and 99.95%, respectively, for the quarter ended December 2022.…

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

-Regulatory submissions complete for exagamglogene autotemcel (exa-cel) in Europe for transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD); U.S.…

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

If approved, CRISPRs first product may deliver blockbuster sales....…

CRISPR Therapeutics AG (CRSP) closed at $50.87 in the latest trading session, marking a -1.24% move from the prior day....…

The gene-editing business has loads of potential, but is it enough to make you rich?...…

Both stocks should be winners if gene-editing therapy exa-cel wins regulatory approvals....…

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company…

CRISPR Therapeutics AG (CRSP) closed at $55.27 in the latest trading session, marking a -1.51% move from the prior day....…

CRISPR Therapeutics AG (CRSP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate…

Kulkarni, Samarth - Vorstand - Tag der Transaktion: 2023-01-27...…

The gene-therapy specialists near-term outlook is quite bullish....…

DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "CRISPR Technology: Global Markets" report has been added to ResearchAndMarkets.coms offering. A $9.2…

Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies....…

Should investors buy this risky biotech stock as the company moves toward bringing its first major treatment to market?...…

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.94, marking a +0.56% move from the previous day....…

These two companies are in very different situations but could generate significant returns for investors....…

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $46.68, moving -1.12% from the previous trading session....…